Article Text

Download PDFPDF

Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis
  1. Kathryn S Taylor1,
  2. Julie Mclellan1,
  3. Jan Y Verbakel1,2,
  4. Jeffrey K Aronson1,
  5. Daniel S Lasserson1,3,
  6. Nicola Pidduck1,
  7. Nia Roberts4,
  8. Susannah Fleming1,
  9. Christopher A O'Callaghan5,
  10. Clare R Bankhead1,
  11. Amitava Banerjee6,
  12. FD Richard Hobbs1,
  13. Rafael Perera1
  1. 1 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  2. 2 Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
  3. 3 Institute of Applied Health Research, University of Birmingham, Birmingham, UK
  4. 4 Bodleian Health Care Libraries, University of Oxford, Oxford, UK
  5. 5 John Radcliffe Hospital, Oxford Radcliffe Hospitals Trust, Oxford, UK
  6. 6 Farr Institute of Health Informatics Research, University College London, London, UK
  1. Correspondence to Julie Mclellan; julie.mclellan{at}phc.ox.ac.uk

Abstract

Objective To evaluate the effects of drug interventions that may modify the progression of chronic kidney disease (CKD) in adults with CKD stages 3 and 4.

Design Systematic review and meta-analysis.

Methods Searching MEDLINE, EMBASE, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, International Clinical Trials Registry Platform, Health Technology Assessment, Science Citation Index, Social Sciences Citation Index, Conference Proceedings Citation Index and Clinical Trials Register, from March 1999 to July 2018, we identified randomised controlled trials (RCTs) of drugs for hypertension, lipid modification, glycaemic control and sodium bicarbonate, compared with placebo, no drug or a drug from another class, in ≥40 adults with CKD stages 3 and/or 4, with at least 2 years of follow-up and reporting renal function (primary outcome), proteinuria, adverse events, maintenance dialysis, transplantation, cardiovascular events, cardiovascular mortality or all-cause mortality. Two reviewers independently screened citations and extracted data. For continuous outcomes, we used the ratio of means (ROM) at the end of the trial in random-effects meta-analyses. We assessed methodological quality with the Cochrane Risk of Bias Tool and confidence in the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.

Results We included 35 RCTs and over 51 000 patients. Data were limited, and heterogeneity varied. Final renal function (estimated glomerular filtration rate) was 6% higher in those taking glycaemic control drugs (ROM 1.06, 95% CI 1.02 to 1.10, I2=0%, low GRADE confidence) and 4% higher in those taking lipid-modifying drugs (ROM 1.04, 95% CI 1.00 to 1.08, I2=88%, very low GRADE confidence). For RCTs of antihypertensive drugs, there were no significant differences in renal function. Treatment with lipid-modifying drugs led to a 36% reduction in cardiovascular disease and 26% reduction in all-cause mortality.

Conclusions Glycaemic control and lipid-modifying drugs may slow the progression of CKD, but we found no pooled evidence of benefit nor harm from antihypertensive drugs. However, given the data limitations, further research is needed to confirm these findings.

PROSPERO registration number CRD42015017501.

  • Chronic renal failure
  • Cardiovascular events
  • Meta-analysis
  • Renal function
  • Drug treatment

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors JM, RP, CRB, JYV, JKA, DSL, CAOC, KT, FDRH and AB were involved in the conception and design of the study. NR, assisted by JM and JKA, devised the search strategy. NR completed the search. JM, NP, KST, JYV and SF selected studies for inclusion, and KST, JM, JYV and NP extracted data. KST carried out the data analysis with advice from RP. KST and JM together wrote the first draft of the manuscript, and all authors contributed critically to subsequent revisions and approved the final manuscript. KST and JM had full access to all data in the study and take responsibility for the integrity and accuracy of the data analysis. KST and JM are guarantors.

  • Funding This article presents independent research funded by the NIHR under the Programme Grants for Applied Research (RP-PG-1210-12003). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

  • Competing interests KST, JM, JKA and SF receive funding from the NIHR Programme for Applied Research. JYV receives funding from the NIHR Community Healthcare MIC, Nuffield Department of Primary Care Health Sciences and University of Oxford NIHR Diagnostic Evidence Co-operative (DEC). DSL receives funding from the NIHR Community Healthcare MIC. FDRH acknowledges his part-funding from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care (CLAHRC) Oxford, the NIHR Oxford Biomedical Research Centre (BRC) (UHT), and the NIHR Oxford Medtech and In Vitro Diagnostics Co-operative (MIC). RP receives funding from the NIHR Oxford Biomedical Research Centre Programme, the NIHR Programme for Applied Research, the NIHR HPRU Gastrointestinal Infections Group, and the NIHR Diagnostic Evidence Co-operative (DEC).

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.